Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$423 Mln
Revenue (TTM)
$8 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.3
Industry P/E
--
EV/EBITDA
0.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$0.8
EPS
$-0.5
Face value
--
Shares outstanding
121,087,249
CFO
$-551.19 Mln
EBITDA
$-661.85 Mln
Net Profit
$-763.85 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics (ACRS)
| 39.5 | 46.3 | 39.5 | 183.8 | -19.6 | -30.8 | -14.7 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics (ACRS)
| 21.4 | 134.5 | -93.3 | 8.3 | 124.7 | 242.3 | -74.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics (ACRS)
|
4.2 | 422.6 | 7.8 | -64.9 | -883.0 | -50.2 | -- | 4.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug... (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 701 Lee Road, Wayne, PA, United States, 19087 Read more
Co-Founder, President, Chairman & Interim CEO
Dr. Neal S. Walker D.O., M.D.
Co-Founder, President, Chairman & Interim CEO
Dr. Neal S. Walker D.O., M.D.
Headquarters
Wayne, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aclaris Therapeutics Inc (ACRS) is $4.20 (NASDAQ) as of 02-Apr-2026 16:01 EDT. Aclaris Therapeutics Inc (ACRS) has given a return of -19.63% in the last 3 years.
Since, TTM earnings of Aclaris Therapeutics Inc (ACRS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.69
|
3.58
|
|
2024
|
-1.79
|
1.52
|
|
2023
|
-0.84
|
0.47
|
|
2022
|
-12.09
|
5.31
|
|
2021
|
-9.80
|
4.51
|
The 52-week high and low of Aclaris Therapeutics Inc (ACRS) are Rs 4.84 and Rs 1.05 as of 05-Apr-2026.
Aclaris Therapeutics Inc (ACRS) has a market capitalisation of $ 423 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aclaris Therapeutics Inc (ACRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.06
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.